Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine

Journal of Virology

Volumn 84, Issue 3, 2010, Pages 1243-1253

  Arrode Brusés, Géraldine ^a   Sheffer, Darlene ^a   Hegde, Ramakrishna ^a   Dhillon, Sukbir ^a   Liu, Zhengian ^a   Villinger, François ^b   Narayan, Opendra ^a   Chebloune, Yahia ^a,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 15;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SINGLE DRUG DOSE; T LYMPHOCYTE;

ANIMALIA; MACACA; MACACA MULATTA; MUS; PRIMATES;

EID: 73949137353     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01846-09     Document Type: Article

References (65)

1. + T-cell efficacy in vaccination and disease. Nat. Med. 14:623-628.
2. Armengol, G., L. M. Ruiz, and S. Orduz. 2004. The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response. Mol. Biotechnol. 27:109-118.
3. + T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur. J. Immunol. 35:159-170.
4. Arrode, G., R. Hegde, Y. Jin, D. K. Singh, O. Narayan, and Y. Chebloune. 2008. Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine. Vaccine 26:3795-3804.
5. + T-cell responses induced by a single injection of a HIV DNA vaccine in mice. J. Immunol. 178:2318-2327.
6. Aung, W., S. Hasegawa, M. Koshikawa-Yano, T. Obata, H. Ikehira, T. Furukawa, I. Aoki, and T. Saga. 2009. Visualization of in vivo electroporation-mediated transgene expression in experimental tumors by optical and magnetic resonance imaging. Gene Ther. 16:830-839.
7. Babiuk, S., M. E. Baca-Estrada, M. Foldvari, D. M. Middleton, D. Rabussay, G. Widera, and L. A. Babiuk. 2004. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J. Biotechnol. 110:1-10.
8. Bansal, A., B. Jackson, K. West, S. Wang, S. Lu, J. S. Kennedy, and P. A. Goepfert. 2008. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J. Virol. 82:6458-6469.
9. + T cell response that is not altered by suppression of viral replication. PLoS One 4:e4408.
10. Barouch, D. H. 2008. Challenges in the development of an HIV-1 vaccine. Nature 455:613-619.
11. + T cells. Blood 107:4781-4789.
12. Chen, H., A. Piechocka-Trocha, T. Miura, M. A. Brockman, B. D. Julg, B. M. Baker, A. C. Rothchild, B. L. Block, A. Schneidewind, T. Koibuchi, F. Pereyra, T. M. Allen, and B. D. Walker. 2009. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J. Virol. 83:3138-3149.
13. Daud, A. I., R. C. DeConti, S. Andrews, P. Urbas, A. I. Riker, V. K. Sondak, P. N. Munster, D. M. Sullivan, K. E. Ugen, J. L. Messina, and R. Heller. 2008. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26:5896-5903.
14. De Rosa, S. D., and M. J. McElrath. 2008. T cell responses generated by HIV vaccines in clinical trials. Curr. Opin. HIV AIDS 3:375-379.
15. Dubie, R. A., S. Maksaereekul, B. L. Shacklett, D. Lemongello, K. S. Cole, F. Villinger, S. A. Blozis, P. A. Luciw, and E. E. Sparger. 2009. Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386:109-121.
16. Fauci, A. S., M. I. Johnston, C. W. Dieffenbach, D. R. Burton, S. M. Hammer, J. A. Hoxie, M. Martin, J. Overbaugh, D. I. Watkins, A. Mahmoud, and W. C. Greene. 2008. HIV vaccine research: the way forward. Science 321: 530-532.
17. Friedrich, T. C., and D. I. Watkins. 2008. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr. Opin. HIV AIDS 3:393-398.
18. Graham, B. S., R. A. Koup, M. Roederer, R. T. Bailer, M. E. Enama, Z. Moodie, J. E. Martin, M. M. McCluskey, B. K. Chakrabarti, L. Lamoreaux, C. A. Andrews, P. L. Gomez, J. R. Mascola, and G. J. Nabel. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194:1650-1660.
19. Hamajima, K., S. Sasaki, J. Fukushima, T. Kaneko, K. Q. Xin, I. Kudoh, and K. Okuda. 1998. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin. Immunol. Immunopathol. 88:205-210.
20. Hansen, S. G., C. Vieville, N. Whizin, L. Coyne-Johnson, D. C. Siess, D. D. Drummond, A. W. Legasse, M. K. Axthelm, K. Oswald, C. M. Trubey, M. Piatak, Jr., J. D. Lifson, J. A. Nelson, M. A. Jarvis, and L. J. Picker. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
21. Hegde, R., Z. Liu, G. Mackay, M. Smith, Y. Chebloune, O. Narayan, and D. K. Singh. 2005. Antigen expression kinetics and immune responses of mice immunized with noninfectious simian-human immunodeficiency virus DNA. J. Virol. 79:14688-14697.
22. Hofmann, F., H. Ohnimus, C. Scheller, W. Strupp, U. Zimmermann, and C. Jassoy. 1999. Electric field pulses can induce apoptosis. J. Membr. Biol. 169:103-109.
23. Horton, H., E. P. Thomas, J. A. Stucky, I. Frank, Z. Moodie, Y. Huang, Y. L. Chiu, M. J. McElrath, and S. C. De Rosa. 2007. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods 323:39-54.
24. Johnson, R. P., R. L. Glickman, J. Q. Yang, A. Kaur, J. T. Dion, M. J. Mulligan, and R. C. Desrosiers. 1997. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71:7711-7718.
25. Johnston, M. I., and A. S. Fauci. 2008. An HIV vaccine-challenges and prospects. N. Engl. J. Med. 359:888-890.
26. Kawada, M., T. Tsukamoto, H. Yamamoto, N. Iwamoto, K. Kurihara, A. Takeda, C. Moriya, H. Takeuchi, H. Akari, and T. Matano. 2008. Gagspecific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J. Virol. 82:10199-10206.
27. Kennedy, J. S., M. Co, S. Green, K. Longtine, J. Longtine, M. A. O'Neill, J. P. Adams, A. L. Rothman, Q. Yu, R. Johnson-Leva, R. Pal, S. Wang, S. Lu, and P. Markham. 2008. The safety and tolerability of an HIV-1 DNA primeprotein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26: 4420-4424.
28. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
29. Korber, B. T., N. L. Letvin, and B. F. Haynes. 2009. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J. Virol. 83:8300-8314.
30. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9:776-788.
31. Kwissa, M., R. R. Amara, H. L. Robinson, B. Moss, S. Alkan, A. Jabbar, F. Villinger, and B. Pulendran. 2007. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J. Exp. Med. 204:2733-2746.
32. Laddy, D. J., J. Yan, A. S. Khan, H. Andersen, A. Cohn, J. Greenhouse, M. Lewis, J. Manischewitz, L. R. King, H. Golding, R. Draghia-Akli, and D. B. Weiner. 2009. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83:4624-4630.
33. Liu, J., M. Hellerstein, M. McDonnel, R. R. Amara, L. S. Wyatt, B. Moss, and H. L. Robinson. 2007. Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost. Vaccine 25:2951-2958.
34. Liu, J., R. Kjeken, I. Mathiesen, and D. H. Barouch. 2008. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82:5643-5649.
35. Liu, Z., D. K. Singh, D. Sheffer, M. S. Smith, S. Dhillon, Y. Chebloune, R. Hegde, S. Buch, and O. Narayan. 2006. Immunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine. Virology 351:444-454.
36. Liu, Z. Q., S. Muhkerjee, M. Sahni, C. McCormick-Davis, K. Leung, Z. Li, V. H. Gattone, Jr., C. Tian, R. W. Doms, T. L. Hoffman, R. Raghavan, O. Narayan, and E. B. Stephens. 1999. Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology 260:295-307.
37. Luckay, A., M. K. Sidhu, R. Kjeken, S. Megati, S. Y. Chong, V. Roopchand, D. Garcia-Hand, R. Abdullah, R. Braun, D. C. Montefiori, M. Rosati, B. K. Felber, G. N. Pavlakis, I. Mathiesen, Z. R. Israel, J. H. Eldridge, and M. A. Egan. 2007. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 81:5257-5269.
38. Makaroff, L. E., D. W. Hendricks, R. E. Niec, and P. J. Fink. 2009. Postthymic maturation influences the CD8 T cell response to antigen. Proc. Natl. Acad. Sci. USA 106:4799-4804.
39. Mansfield, K., S. M. Lang, M. C. Gauduin, H. B. Sanford, J. D. Lifson, R. P. Johnson, and R. C. Desrosiers. 2008. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J. Virol. 82:4135-4148.
40. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3:1061-1068.
41. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009-1021.
42. Mulligan, M. J., N. D. Russell, C. Celum, J. Kahn, E. Noonan, D. C. Montefiori, G. Ferrari, K. J. Weinhold, J. M. Smith, R. R. Amara, and H. L. Robinson. 2006. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retrovir. 22:678-683.
43. Nchinda, G., J. Kuroiwa, M. Oks, C. Trumpfheller, C. G. Park, Y. Huang, D. Hannaman, S. J. Schlesinger, O. Mizenina, M. C. Nussenzweig, K. Uberla, and R. M. Steinman. 2008. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Investig. 118:1427-1436.
44. Orság, P., V. Kvardova, M. Raska, A. D. Miller, M. Ledvina, and J. Turanek. 2008. Quantitative real-time PCR study on persistence of pDNA vaccine pVax-Hsp60 TM814 in beef muscles. Genet. Vaccines Ther. 6:11.
45. Pantaleo, G., and R. A. Koup. 2004. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat. Med. 10:806-810.
46. Piñero, J., M. Lopez-Baena, T. Ortiz, and F. Cortes. 1997. Apoptotic and necrotic cell death are both induced by electroporation in HL60 human promyeloid leukaemia cells. Apoptosis 2:330-336.
47. Reynolds, M. R., A. M. Weiler, K. L. Weisgrau, S. M. Piaskowski, J. R. Furlott, J. T. Weinfurter, M. Kaizu, T. Soma, E. J. Leon, C. MacNair, D. P. Leaman, M. B. Zwick, E. Gostick, S. K. Musani, D. A. Price, T. C. Friedrich, E. G. Rakasz, N. A. Wilson, A. B. McDermott, R. Boyle, D. B. Allison, D. R. Burton, W. C. Koff, and D. I. Watkins. 2008. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 205:2537-2550.
48. Robb, M. L. 2008. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372:1857-1858.
49. Robinson, H. L., and K. J. Weinhold. 2006. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. J. Infect. Dis. 194:1625-1627.
50. Rosati, M., A. Valentin, R. Jalah, V. Patel, A. von Gegerfelt, C. Bergamaschi, C. Alicea, D. Weiss, J. Treece, R. Pal, P. D. Markham, E. T. Marques, J. T. August, A. Khan, R. Draghia-Akli, B. K. Felber, and G. N. Pavlakis. 2008. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26:5223-5229.
51. Sasaki, S., K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. R. Kensil, and K. Okuda. 1998. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 72:4931-4939.
52. Sattentau, Q. 2008. Correlates of antibody-mediated protection against HIV infection. Curr. Opin. HIV AIDS 3:368-374.
53. Sekaly, R. P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12.
54. Singh, D. K., Z. Liu, D. Sheffer, G. A. Mackay, M. Smith, S. Dhillon, R. Hegde, F. Jia, I. Adany, and O. Narayan. 2005. A noninfectious simian/ human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J. Virol. 79:3419-3428.
55. Smith, M. S., Y. Niu, Z. Li, I. Adany, D. M. Pinson, Z. Q. Liu, T. Berry, D. Sheffer, F. Jia, and O. Narayan. 2002. Systemic infection and limited replication of SHIV vaccine virus in brains of macaques inoculated intracerebrally with infectious viral DNA. Virology 301:130-135.
56. Stacey, K. J., I. L. Ross, and D. A. Hume. 1993. Electroporation and DNAdependent cell death in murine macrophages. Immunol. Cell Biol. 71:75-85.
57. Villinger, F., S. S. Brar, A. Mayne, N. Chikkala, and A. A. Ansari. 1995. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J. Immunol. 155:3946-3954.
58. Wahid, R., R. Salerno-Goncalves, C. O. Tacket, M. M. Levine, and M. B. Sztein. 2008. Generation of specific effector and memory T cells with gutand secondary lymphoid tissue-homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol. 1:389-398.
59. Watkins, D. I., D. R. Burton, E. G. Kallas, J. P. Moore, and W. C. Koff. 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14:617-621.
60. Weaver, J. C. 1993. Electroporation: a general phenomenon for manipulating cells and tissues. J. Cell Biochem. 51:426-435.
61. Wyand, M. S., K. Manson, D. C. Montefiori, J. D. Lifson, R. P. Johnson, and R. C. Desrosiers. 1999. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 73:8356-8363.
62. Yan, J., D. A. Hokey, M. P. Morrow, N. Corbitt, K. Harris, D. Harris, and D. B. Weiner. 2009. Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine 27:3260-3266.
63. Yan, J., H. Yoon, S. Kumar, M. P. Ramanathan, N. Corbitt, M. Kutzler, A. Dai, J. D. Boyer, and D. B. Weiner. 2007. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol. Ther. 15:411-421.
64. Yankee, T. M., D. Sheffer, Z. Liu, S. Dhillon, F. Jia, Y. Chebloune, E. B. Stephens, and O. Narayan. 2009. Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques. Virology 383:103-111.
65. Zuñiga, R., A. Lucchetti, P. Galvan, S. Sanchez, C. Sanchez, A. Hernandez, H. Sanchez, N. Frahm, C. H. Linde, H. S. Hewitt, W. Hildebrand, M. Altfeld, T. M. Allen, B. D. Walker, B. T. Korber, T. Leitner, J. Sanchez, and C. Brander. 2006. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 80:3122-3125.